RiverVest Venture Partners

Investing in Life Science Innovation

 
  • Home
  • About Us
  • Team
  • Portfolio
  • Case Studies
  • News
    • All News
    • RiverVest News
    • Newsletters
  • Contact Us

RiverVest News – Spring 2019

RiverVest closes on its oversubscribed $184.4 million RiverVest Fund IV

The fund marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Dec. 31 to $832 million.

Also in this issue:
RiverVest recognized as Investor of the Year
Sivan Weitzman joins RiverVest as its first CFO
Portfolio company news from Allakos, Arch Oncology, Cardialen, Mirum Pharmaceuticals, Spruce Bioscience and WUGEN

RiverVest News – Fall/Winter 2017

RiverVest Expands Scientific Advisory Board

RiverVest Venture Partners announced today that Ronald T. Borchardt, Ph.D. and Jared Rutter, Ph.D. have joined the life science venture capital firm’s Scientific Advisory Board.

Also in this issue:
Portfolio company news from Allakos, Amplyx, Avalyn Pharma, Spruce Biosciences, Tryton Medical and VentureMed Group

RiverVest News – Winter 2017

RiverVest Closes on $15 Million Biopharma Seed Fund

RiverVest’s new Archer Seed Fund will invest pre-seed and seed funding in about 10 early-stage  biopharma companies. Investment opportunities will be sourced primarily from leading medical research institutions in St. Louis, the Midwest, and elsewhere in the U.S.

Also in this issue:
Karen Gheesling Mullis joins RiverVest
RiverVest Annual Meeting is April 11, 2017
Portfolio company news from Allakos, Amplyx, Tioma and Tryton

read-more-box

 

RiverVest News – Summer 2016

RiverVest Venture Partners Co-leads $86 million Series A Financing for St. Louis-founded Startup Tioma.

“Thmckearnis is a fantastic example of what St. Louis-based innovation, talent and resources can do to build biopharma companies that will make a difference,” said John McKearn, RiverVest managing director and Tioma board chairman.

Also in this issue:
RiverVest’s Fund II Continues to perform in Top 5% of VC funds
RiverVest Adds Analyst in St. Louis Office
Portfolio company news from Allakos, Amplyx, Otonomy and Securus

read-more-box

 

RiverVest News – Spring 2016

Nancy Hong Joins RiverVest.

Nancy A. Hong, Ph.D.
Nancy A. Hong, Ph.D.

“Nancy has a great history identifying successful investments,” said RiverVest Managing Director and co-founder Jay Schmelter. “She brings both scientific and transactional expertise and is well respected for her opinions and views on the venture industry. We’re excited to have her join the team.”

 

Also in this issue:
RiverVest’s Fund III has Strong Start
RiverVest’s Fund II Performs in Top 5% of VC Funds
Portfolio company news from Allakos, Amplyx, Otonomy and Vasculox

read-more-box

 

2015 Spring Newsletter

2015 Spring RiverVest Newsletter

Download PDF

2015 Spring RiverVest Newsletter

2013 Spring Newsletter

Spring 2013: RiverVest startup brings proven drug back to clinic for promising new application

What if you could create a biotech startup focused on treating rare diseases, with clinical-stage drug candidates already in hand, and high odds of success in clinical trials?

2012 Spring Newsletter

Spring 2012: RiverVest closes on four deals, exceeds industry benchmarks

RiverVest Venture Partners’ hands-on investment strategy netted big returns for its Fund I and II investors in 2011: the sale of two biopharmaceutical and two medical device companies, worth more than $1 billion.

2010 Winter Newsletter

Winter 2010: RiverVest co-leads $38.5 million Series B financing to advance breakthrough treatment for ear disorders

Otonomy, Inc. is on the verge of revolutionizing the way doctors treat hearing and balance disorders. “The ear is one of the last great frontiers of pharmaceutical science,” says Jay Lichter, Ph.D., co-founder of Otonomy.

2009 Spring Newsletter

Spring 2009:  RiverVest invests in Mpex Pharmaceuticals Series D financing

Mpex Pharmaceiticals will soon complete patient enrollment for two Phase II clinical trials for its proprietary MP-376 inhaled antibiotic formulation aided by a $27.5 million capital infusion led by Investor Growth Capital.

2008 Spring Newsletter

Spring 2008:  RiverVest founds and co-leads Excaliard with $15.5 million investment to fund fibrotic disease treatment

RiverVest Venture Partners, in an oversubscribed syndication with Alta Partners and ProQuest Investments, closed in November on a $15.5 million Series A financing of Excaliard Pharmaceuticals.

2007 Spring Newsletter

Spring 2007:  IDev Technologies: RiverVest leads investment in promising treatment for peripheral artery disease

RiverVest Venture Partners recently led a $19 million Series B financing round for IDev Technologies, Inc., an emerging leader in the treatment of peripheral artery disease (PAD) through the development and marketing of the SUPERA stent system. Joining RiverVest in the Series B round was Bay City Capital, a San Francisco based venture capital firm.

  • 1
  • 2
  • Next Page »

RiverVest Venture Partners

St. Louis Office
101 S. Hanley Road, Suite 1850
St. Louis, MO 63105
Phone: 314.726.6700
Fax: 314.726.6715
info@rivervest.com

San Diego Office
12730 High Bluff Drive, Suite 160
San Diego, CA 92130
Fax: 314.726.6715
info@rivervest.com

Cleveland Office
11000 Cedar Avenue, Suite 100
Cleveland, OH 44106
Phone: 216.658.3982
Fax: 314.726.6715
info@rivervest.com

  • LinkedIn
  • Twitter

Newsletter Sign Up

Copyright © 2019 RiverVest · All Rights Reserved · Powered by NeuConcept

Copyright © 2019 · RiverVest on Genesis Framework · WordPress · Log in